Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.

Axel Stenmark Tullberg Martin Sjöström Emma Nimeús Fredrika Killander S Laura Chang Felix Y Feng Corey W Speers Lori J Pierce Anikó Kovacs Dan Lundstedt Erik Carl Viktor Holmberg Per Karsson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Integrating tumor-intrinsic and immunologic factors may identify immunogenic tumors in early-stage breast cancer populations dominated by ER-positive tumors. Patients who benefit from an activated immune infiltrate may be candidates for RT de-escalation.

Keyphrases

early stage
phase iii
open label
phase ii
double blind
clinical trial
study protocol
randomized controlled trial
radiation therapy
young adults
endoplasmic reticulum
breast cancer cells
sentinel lymph node
lymph node
estrogen receptor